Form 8-K
Washington, D.C. 20549


Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event report): April 1, 2006

(Exact name of registrant as specified in its charter)
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification Number)

711 NE 39th Street, Oklahoma City, OK 73105
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (405) 842-0131

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Information to be Included in the Report

ITEM 1.01. Entry into a Material Definitive Agreement.

On April 1, 2006, AMS Health Sciences, Inc. (the “Company”) and Robin L. Jacob entered into an Employment Agreement effective February 12, 2006 (the “Agreement”), which provides, among other things, that Ms. Jacob will serve as the Vice President, Secretary, Treasurer and Chief Financial Officer of the Company for an initial term of two years (the “Initial Term”), followed by two successive one-year terms unless either party elects not to renew the Agreement. Ms. Jacob’s base salary is $100,000 per year for the first year of the Initial Term, $112,500 for the second year of the Initial Term and $125,000 for each year after the Initial Term. Additionally, she is eligible to receive certain performance-based incentive bonuses. The Company granted Ms. Jacob options to purchase 150,000 shares of the Company’s common stock at an exercise price of $.64 per share, which was the closing price of the Company’s common stock on March 31, 2006, the last trading day prior to the date the options were granted. The options vest in five equal annual installments beginning April 1, 2007 and expire April 1, 2016. In the event the Company terminates Ms. Jacob without cause, she will receive certain severance pay based upon her length of employment with the Company. A copy of the Agreement is attached hereto as Exhibit 10.11.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits

10.11 Employment Agreement between AMS Health Sciences, Inc., and Robin L. Jacob


Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

                   /S/ ROBIN L. JACOB
                       By: Robin L. Jacob
                   Vice President and CFO
Date: April 12, 2006



Exhibit No.
Method of Filing
Robin L. Jacob employment agreement
Filed herewith